|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, June 24, 2017 ) This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.
Publisher's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
For more information about this report at http://www.reportsweb.com/hepatitis-c-pipeline-review-h1-2015
Report Scope
- The report provides a snapshot of the global therapeutic landscape of Hepatitis C
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hepatitis C and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hepatitis C pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Request a sample copy at http://www.reportsweb.com/inquiry&RW0001172443/sample
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hepatitis C
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Company profiles
3-V Biosciences, Inc.
AbbVie Inc.
Achillion Pharmaceuticals, Inc.
Adaptimmune Limited
AiCuris GmbH & Co. KG
AIMM Therapeutics B.V.
Akshaya Bio Inc.
Alnylam Pharmaceuticals, Inc.
Altor BioScience Corporation
Amarna Therapeutics B.V.
American Gene Technologies International Inc.
Anacor Pharmaceuticals, Inc.
ARA Healthcare Pvt. Ltd.
Arrowhead Research Corporation
Ascendis Pharma A/S
Astex Pharmaceuticals, Inc.
Biogenomics Limited
BioLineRx, Ltd.
Bionor Pharma ASA
Biotest AG
Biotron Limited
Bolder Biotechnology, Inc.
Bristol-Myers Squibb Company
Celgene Corporation
Chiasma, Inc.
Chugai Pharmaceutical Co., Ltd.
Cocrystal Pharma, Inc.
Conatus Pharmaceuticals Inc.
Crucell N.V.
Debiopharm International S.A.
DEKK-TEC, Inc.
Delpor, Inc.
Digna Biotech, S.L.
DiscoveryBiomed, Inc.
Enanta Pharmaceuticals, Inc.
F. Hoffmann-La Roche Ltd.
Genecode AS
GeneCure LLC
Gilead Sciences, Inc.
GlaxoSmithKline plc
HanAll Biopharma Co., Ltd.
Hanmi Pharmaceuticals, Co. Ltd.
HEC Pharm Co., Ltd.
Hepacyl Therapeutics, SL
Hependo Sp. z o. o. (Ltd)
Hetero Drugs Limited
Humabs BioMed SA
ImmunoBiology Ltd.
Immunocore Limited
Immunomedics, Inc.
Immunotech Laboratories, Inc.
Inbiopro Solutions Pvt. Ltd.
Inovio Pharmaceuticals, Inc.
Integrated BioTherapeutics, Inc.
iTherX, Inc.
Johnson & Johnson
Kineta, Inc.
Koronis Pharma, Inc.
LG Life Sciences, Ltd.
Ligand Pharmaceuticals, Inc.
Meda AB
Medivir AB
Merck & Co., Inc.
Microbio Co., Ltd.
Microbiotix, Inc.
Myelo Therapeutics GmbH
Novartis AG
Oncolys BioPharma Inc.
Ono Pharmaceutical Co., Ltd.
Peregrine Pharmaceuticals, Inc.
Pfenex Inc.
Pfizer Inc.
PharmaEssentia Corporation
Polaris Pharmaceuticals, Inc.
Presidio Pharmaceuticals, Inc.
Profectus BioSciences, Inc.
Quintessence Biosciences, Inc.
Regulus Therapeutics Inc.
RFS Pharma, LLC
Rodos BioTarget GmbH
Romark Laboratories, L.C.
Seek
SelectX Pharmaceuticals, Inc.
SKAU Vaccines ApS
SomaGenics Inc.
Sorrento Therapeutics, Inc.
Spring Bank Pharmaceuticals, Inc.
StemCells, Inc.
Summit Corporation plc
Tacere Therapeutics, Inc.
TaiGen Biotechnology Co., Ltd.
Therapure Biopharma Inc.
Theravectys S.A.
Transgene SA
United Therapeutics Corporation
Vakzine Projekt Management GmbH
Vaxeal Holding SA
VBI Vaccines
Vertex Pharmaceuticals Incorporated
ViroLogik GmbH
WaterStone Pharmaceuticals, Inc.
WhanIn Pharmaceutical Co., Ltd.
Xenetic Biosciences plc
Ask for Discount at http://www.reportsweb.com/inquiry&RW0001172443/discount
List of Tables
Number of Products under Development for Hepatitis C, H1 2015 36
Number of Products under Development for Hepatitis C-Comparative Analysis, H1 2015 37
Number of Products under Development by Companies, H1 2015 39
Number of Products under Development by Companies, H1 2015 (Contd..1) 40
Number of Products under Development by Companies, H1 2015 (Contd..2) 41
Number of Products under Development by Companies, H1 2015 (Contd..3) 42
Number of Products under Development by Companies, H1 2015 (Contd..4) 43
Number of Products under Development by Companies, H1 2015 (Contd..5) 44
Number of Products under Development by Companies, H1 2015 (Contd..6) 45
Number of Products under Development by Companies, H1 2015 (Contd..7) 46
Number of Products under Investigation by Universities/Institutes, H1 2015 48
Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 49
Comparative Analysis by Late Stage Development, H1 2015 50
Comparative Analysis by Clinical Stage Development, H1 2015 51
Comparative Analysis by Early Stage Development, H1 2015 52
Comparative Analysis by Unknown Stage Development, H1 2015 53
Products under Development by Companies, H1 2015 54
Products under Development by Companies, H1 2015 (Contd..1) 55
Products under Development by Companies, H1 2015 (Contd..2) 56
Products under Development by Companies, H1 2015 (Contd..3) 57
Products under Development by Companies, H1 2015 (Contd..4) 58
Products under Development by Companies, H1 2015 (Contd..5) 59
Products under Development by Companies, H1 2015 (Contd..6) 60
Products under Development by Companies, H1 2015 (Contd..7) 61
Products under Development by Companies, H1 2015 (Contd..8) 62
Products under Development by Companies, H1 2015 (Contd..9) 63
Products under Development by Companies, H1 2015 (Contd..10) 64
Products under Development by Companies, H1 2015 (Contd..11) 65
Products under Development by Companies, H1 2015 (Contd..12) 66
Products under Development by Companies, H1 2015 (Contd..13) 67
Products under Development by Companies, H1 2015 (Contd..14) 68
Products under Investigation by Universities/Institutes, H1 2015 69
Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 70
Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 71
Hepatitis C-Pipeline by 3-V Biosciences, Inc., H1 2015 72
Hepatitis C-Pipeline by AbbVie Inc., H1 2015 73
Hepatitis C-Pipeline by Achillion Pharmaceuticals, Inc., H1 2015 74
Hepatitis C-Pipeline by Adaptimmune Limited, H1 2015 75
Hepatitis C-Pipeline by AiCuris GmbH & Co. KG, H1 2015 76
Hepatitis C-Pipeline by AIMM Therapeutics B.V., H1 2015 77
Hepatitis C-Pipeline by Akshaya Bio Inc., H1 2015 78
Hepatitis C-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 79
Hepatitis C-Pipeline by Altor BioScience Corporation, H1 2015 80
Hepatitis C-Pipeline by Amarna Therapeutics B.V., H1 2015 81
Hepatitis C-Pipeline by American Gene Technologies International Inc., H1 2015 82
Hepatitis C-Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 83
Hepatitis C-Pipeline by ARA Healthcare Pvt. Ltd., H1 2015 84
Hepatitis C-Pipeline by Arrowhead Research Corporation, H1 2015 85
Hepatitis C-Pipeline by Ascendis Pharma A/S, H1 2015 86
Hepatitis C-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 87
Hepatitis C-Pipeline by Biogenomics Limited, H1 2015 88
Hepatitis C-Pipeline by BioLineRx, Ltd., H1 2015 89
Hepatitis C-Pipeline by Bionor Pharma ASA, H1 2015 90
Hepatitis C-Pipeline by Biotest AG, H1 2015 91
Hepatitis C-Pipeline by Biotron Limited, H1 2015 92
Hepatitis C-Pipeline by Bolder Biotechnology, Inc., H1 2015 93
Hepatitis C-Pipeline by Bristol-Myers Squibb Company, H1 2015 94
Hepatitis C-Pipeline by Celgene Corporation, H1 2015 95
Hepatitis C-Pipeline by Chiasma, Inc., H1 2015 96
Hepatitis C-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 97
Hepatitis C-Pipeline by Cocrystal Pharma, Inc., H1 2015 98
Hepatitis C-Pipeline by Conatus Pharmaceuticals Inc., H1 2015 99
Hepatitis C-Pipeline by Crucell N.V., H1 2015 100
Hepatitis C-Pipeline by Debiopharm International S.A., H1 2015 101
Hepatitis C-Pipeline by DEKK-TEC, Inc., H1 2015 102
Hepatitis C-Pipeline by Delpor, Inc., H1 2015 103
Hepatitis C-Pipeline by Digna Biotech, S.L., H1 2015 104
Hepatitis C-Pipeline by DiscoveryBiomed, Inc., H1 2015 105
Hepatitis C-Pipeline by Enanta Pharmaceuticals, Inc., H1 2015 106
Hepatitis C-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 107
Hepatitis C-Pipeline by Genecode AS, H1 2015 108
Hepatitis C-Pipeline by GeneCure LLC, H1 2015 109
Hepatitis C-Pipeline by Gilead Sciences, Inc., H1 2015 110
Hepatitis C-Pipeline by GlaxoSmithKline plc, H1 2015 111
Hepatitis C-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 112
Hepatitis C-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 113
Hepatitis C-Pipeline by HEC Pharm Co., Ltd., H1 2015 114
Hepatitis C-Pipeline by Hepacyl Therapeutics, SL, H1 2015 115
Hepatitis C-Pipeline by Hependo Sp. z o. o. (Ltd), H1 2015 116
Hepatitis C-Pipeline by Hetero Drugs Limited, H1 2015 117
Hepatitis C-Pipeline by Humabs BioMed SA, H1 2015 118
Hepatitis C-Pipeline by ImmunoBiology Ltd., H1 2015 119
Hepatitis C-Pipeline by Immunocore Limited, H1 2015 120
Hepatitis C-Pipeline by Immunomedics, Inc., H1 2015 121
Hepatitis C-Pipeline by Immunotech Laboratories, Inc., H1 2015 122
Hepatitis C-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 123
Hepatitis C-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 124
Hepatitis C-Pipeline by Integrated BioTherapeutics, Inc., H1 2015 125
Hepatitis C-Pipeline by iTherX, Inc., H1 2015 126
Hepatitis C-Pipeline by Johnson & Johnson, H1 2015 127
Hepatitis C-Pipeline by Kineta, Inc., H1 2015 128
Hepatitis C-Pipeline by Koronis Pharma, Inc., H1 2015 129
Hepatitis C-Pipeline by LG Life Sciences, Ltd., H1 2015 130
Hepatitis C-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 131
Hepatitis C-Pipeline by Meda AB, H1 2015 132
Hepatitis C-Pipeline by Medivir AB, H1 2015 133
Hepatitis C-Pipeline by Merck & Co., Inc., H1 2015 134
Hepatitis C-Pipeline by Microbio Co., Ltd., H1 2015 135
Hepatitis C-Pipeline by Microbiotix, Inc., H1 2015 136
Hepatitis C-Pipeline by Myelo Therapeutics GmbH, H1 2015 137
Hepatitis C-Pipeline by Novartis AG, H1 2015 138
Hepatitis C-Pipeline by Oncolys BioPharma Inc., H1 2015 139
Hepatitis C-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 140
Hepatitis C-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 141
Hepatitis C-Pipeline by Pfenex Inc., H1 2015 142
Hepatitis C-Pipeline by Pfizer Inc., H1 2015 143
Hepatitis C-Pipeline by PharmaEssentia Corporation, H1 2015 144
Hepatitis C-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 145
Hepatitis C-Pipeline by Presidio Pharmaceuticals, Inc., H1 2015 146
Hepatitis C-Pipeline by Profectus BioSciences, Inc., H1 2015 147
Hepatitis C-Pipeline by Quintessence Biosciences, Inc., H1 2015 148
Hepatitis C-Pipeline by Regulus Therapeutics Inc., H1 2015 149
Hepatitis C-Pipeline by RFS Pharma, LLC, H1 2015 150
Hepatitis C-Pipeline by Rodos BioTarget GmbH, H1 2015 151
Hepatitis C-Pipeline by Romark Laboratories, L.C., H1 2015 152
Hepatitis C-Pipeline by Seek, H1 2015 153
Hepatitis C-Pipeline by SelectX Pharmaceuticals, Inc., H1 2015 154
Hepatitis C-Pipeline by SKAU Vaccines ApS, H1 2015 155
Hepatitis C-Pipeline by SomaGenics Inc., H1 2015 156
Hepatitis C-Pipeline by Sorrento Therapeutics, Inc., H1 2015 157
Hepatitis C-Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2015 158
Hepatitis C-Pipeline by StemCells, Inc., H1 2015 159
Hepatitis C-Pipeline by Summit Corporation plc, H1 2015 160
Hepatitis C-Pipeline by Tacere Therapeutics, Inc., H1 2015 161
Hepatitis C-Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 162
Hepatitis C-Pipeline by Therapure Biopharma Inc., H1 2015 163
Hepatitis C-Pipeline by Theravectys S.A., H1 2015 164
Hepatitis C-Pipeline by Transgene SA, H1 2015 165
Hepatitis C-Pipeline by United Therapeutics Corporation, H1 2015 166
Hepatitis C-Pipeline by Vakzine Projekt Management GmbH, H1 2015 167
Hepatitis C-Pipeline by Vaxeal Holding SA, H1 2015 168
Hepatitis C-Pipeline by VBI Vaccines, H1 2015 169
Hepatitis C-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 170
Hepatitis C-Pipeline by ViroLogik GmbH, H1 2015 171
Hepatitis C-Pipeline by WaterStone Pharmaceuticals, Inc., H1 2015 172
Hepatitis C-Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2015 173
Hepatitis C-Pipeline by Xenetic Biosciences plc, H1 2015 174
Assessment by Monotherapy Products, H1 2015 175
Assessment by Combination Products, H1 2015 176
Number of Products by Stage and Target, H1 2015 178
Number of Products by Stage and Mechanism of Action, H1 2015 184
Number of Products by Stage and Route of Administration, H1 2015 188
Number of Products by Stage and Molecule Type, H1 2015 190
Hepatitis C Therapeutics-Recent Pipeline Updates, H1 2015 509
Hepatitis C-Dormant Projects, H1 2015 602
Hepatitis C-Dormant Projects (Contd..1), H1 2015 603
Hepatitis C-Dormant Projects (Contd..2), H1 2015 604
Hepatitis C-Dormant Projects (Contd..3), H1 2015 605
Hepatitis C-Dormant Projects (Contd..4), H1 2015 606
Hepatitis C-Dormant Projects (Contd..5), H1 2015 607
Hepatitis C-Dormant Projects (Contd..6), H1 2015 608
Hepatitis C-Dormant Projects (Contd..7), H1 2015 609
Hepatitis C-Dormant Projects (Contd..8), H1 2015 610
Hepatitis C-Dormant Projects (Contd..9), H1 2015 611
Hepatitis C-Dormant Projects (Contd..10), H1 2015 612
Hepatitis C-Dormant Projects (Contd..11), H1 2015 613
Hepatitis C-Dormant Projects (Contd..12), H1 2015 614
Hepatitis C-Dormant Projects (Contd..13), H1 2015 615
Hepatitis C-Dormant Projects (Contd..14), H1 2015 616
Hepatitis C-Dormant Projects (Contd..15), H1 2015 617
Hepatitis C-Dormant Projects (Contd..16), H1 2015 618
Hepatitis C-Dormant Projects (Contd..17), H1 2015 619
Hepatitis C-Dormant Projects (Contd..18), H1 2015 620
Hepatitis C-Discontinued Products, H1 2015 621
Hepatitis C-Discontinued Products (Contd..1), H1 2015 622
Hepatitis C-Discontinued Products (Contd..2), H1 2015 623
Hepatitis C-Discontinued Products (Contd..3), H1 2015 624
Hepatitis C-Discontinued Products (Contd..4), H1 2015 625
Hepatitis C-Discontinued Products (Contd..5), H1 2015 626
Hepatitis C-Discontinued Products (Contd..6), H1 2015 627
Hepatitis C-Discontinued Products (Contd..7), H1 2015 628
Purchase Complete Report at http://www.reportsweb.com/buy&RW0001172443/buy/2000
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
